PMID- 19641379
OWN - NLM
STAT- MEDLINE
DCOM- 20100128
LR  - 20211020
IS  - 2092-6413 (Electronic)
IS  - 1226-3613 (Print)
IS  - 1226-3613 (Linking)
VI  - 41
IP  - 11
DP  - 2009 Nov 30
TI  - Effect of nicotinamide on early graft failure following intraportal islet 
      transplantation.
PG  - 782-92
LID - 10.3858/emm.2009.41.11.084 [doi]
AB  - Intraportal islet transplantation (IPIT) may potentially cure Type 1 diabetes 
      mellitus; however, graft failure in the early post-transplantation period 
      presents a major obstacle. In this study, we tested the ability of nicotinamide 
      to prevent early islet destruction in a syngeneic mouse model. Mice (C57BL/6) 
      with chemically-induced diabetes received intraportal transplants of syngeneic 
      islet tissue in various doses. Islets were cultured for 24 h in medium with or 
      without 10 mM nicotinamide supplementation. Following IPIT, islet function was 
      confirmed by an intraperitoneal glucose tolerance test (IPGTT) and hepatectomy. 
      The effects of nicotinamide were evaluated by blood glucose concentration, serum 
      monocyte chemoattractant protein-1 (MCP-1) concentration, and immunohistology at 
      3 h and 24 h after IPIT. Among the various islet doses, an infusion of 300 
      syngeneic islets treated with nicotinamide exhibited the greatest differences in 
      glucose tolerance between recipients of treated and untreated (i.e., control) 
      islets. One day after 300 islet equivalent (IEQ) transplantation, islets treated 
      with nicotinamide were better granulated than the untreated islets (P=0.01), and 
      the recipients displayed a slight decrease in serum MCP-1 concentration, as 
      compared to controls. After 15 days, recipients of nicotinamide-pretreated islets 
      showed higher levels of graft function (as measured by IPGTT) than controls. The 
      pretreatment also prolonged graft survival (>100 days) and function; these were 
      confirmed by partial hepatectomy, which led to the recurrence of diabetes. 
      Pretreatment of islet grafts with nicotinamide may prevent their deterioration on 
      the early period following IPIT in a syngeneic mouse model.
FAU - Jung, Da-Yeon
AU  - Jung DY
AD  - Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, 
      Korea.
FAU - Park, Jae Berm
AU  - Park JB
FAU - Joo, Sung-Yeon
AU  - Joo SY
FAU - Joh, Jae-Won
AU  - Joh JW
FAU - Kwon, Choon-Hyuck
AU  - Kwon CH
FAU - Kwon, Ghee-Young
AU  - Kwon GY
FAU - Kim, Sung-Joo
AU  - Kim SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Exp Mol Med
JT  - Experimental & molecular medicine
JID - 9607880
RN  - 0 (Blood Glucose)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 12001-76-2 (Vitamin B Complex)
RN  - 25X51I8RD4 (Niacinamide)
SB  - IM
MH  - Animals
MH  - Blood Glucose/metabolism
MH  - Chemokine CCL2/blood
MH  - Diabetes Mellitus, Experimental/blood/*therapy
MH  - Diabetes Mellitus, Type 1/blood/*therapy
MH  - Glucose Tolerance Test
MH  - Graft Rejection
MH  - Graft Survival/drug effects
MH  - Insulin-Secreting Cells/metabolism
MH  - *Islets of Langerhans Transplantation
MH  - Mice
MH  - Niacinamide/adverse effects/*pharmacology
MH  - Time Factors
MH  - Transplantation, Homologous
MH  - Vitamin B Complex/adverse effects/*pharmacology
PMC - PMC2788732
EDAT- 2009/07/31 09:00
MHDA- 2010/01/29 06:00
PMCR- 2009/11/30
CRDT- 2009/07/31 09:00
PHST- 2009/07/31 09:00 [entrez]
PHST- 2009/07/31 09:00 [pubmed]
PHST- 2010/01/29 06:00 [medline]
PHST- 2009/11/30 00:00 [pmc-release]
AID - 10.3858/emm.2009.41.11.084 [doi]
PST - ppublish
SO  - Exp Mol Med. 2009 Nov 30;41(11):782-92. doi: 10.3858/emm.2009.41.11.084.